What is the long term efficacy of betahistine dihydrochloride on the incidence of vertigo attacks in patients with Meniere’s disease, compared with placebo?
Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramida…
The mouse mdr1a (also called mdr3) P-GP is abundant in the blood-brain barrier, and its absence in mdr1a (-/-) mice leads to highly increased levels of the drugs ivermectin, vinblastine, digoxin, and cyclosporin A in the brain. We show here that the drugs loperamide, domperidone, and ondansetron are transported substrates for the mouse mdr1a P-GP and its human homologue MDR1. Phenytoin is a rel…
Over the last several years there has been a great increase in interest for liquid and dissolve-in-the-mouth dosage forms. This interest is spurred by the promise of improved patient compliance compared to tables and capsules, that have to be swallowed whole
Orally disintegrating tablets (ODT) are solid dosage forms that disintegrate in the oral cavity leaving an easy-to-swallow residue.The disintegration times are generally less than one minute.For orally disintegrating tablets,taste-masking of bitter or objectional-tasting drug substances is critical.The taste-masking aspect plays a significant role in dissolution method development,specification…
The demand for fast-melting tablets (FMTs) has been growing during the last decade, particularly for children and the elderly who have difficulty swallowing tablets and capsules.
Japanese patients with total cholesterol (TC)≥220 mg/dL were randomized to receive pitavastatin 2mg (n = 126) or atorvastatin 10 mg (n = 125) for 12 weeks. The primary endpoint was percent change from baseline in non-HDL-C level after 12 weeks of treatment. Reduction of non-HDL-C by pitavastatin treatment (39.0%, P = 0.456 vs. atorvastatin) was non-inferior to that by atorvastatin (40.3%). B…
Pitavastatin (CAS 147526-32-7, NK-104), the first totally synthetic 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor discovered in Japan, was examined. Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1 mg/day or more, and significant dose-dependence of the effect of this drug was ob…
Results froma Phase III, European, non-inferiority trial in elderly (age Z65 years) patients with primary hyperlipidemia or mixed(combined) dyslipidemia demonstrated significantly greater reductions in LDL-C for pitavastatin versus pravastatin across 3pair-wise dose comparisons (1mgvs10mg,2 mgvs20mg, and4mgvs40mg, respectively). The present study investigated whether pitavastatin 4mg is superi…
The demand of fast-melting tablets has been growing during the last decade. This dosage form is placed in the mouth, allowed to disperse or dissolve in the saliva, and then swallowed. In addition, it can be administered anywhere, without the need for water or chewing. Due its features, the fast-melting tablets will increase patient compliance, especially those who need rapid relief, such as vom…